Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycobacterium recombinant vaccines.

A H Labidi1, R C Estes, H L David

  • 1Cytoclonal Pharmaceutics Inc., Vaccine Program, 1720 Regal Row Suite 215, Dallas, Texas 75235, USA.

La Tunisie Medicale
|June 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors.

The Journal of antimicrobial chemotherapy·2000
Same author

Analysis of beta-tubulin cDNAs from taxol-resistant Pestalotiopsis microspora and taxol-sensitive Pythium ultimum and comparison of the taxol-binding properties of their products.

Molecular & general genetics : MGG·2000
Same author

An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon.

Proceedings of the National Academy of Sciences of the United States of America·1997
Same author

Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5.

Microbiology (Reading, England)·1997
Same author

Circulating immune complexes in leprosy sera: demonstration of antibodies against mycobacterial glycolipidic antigens in isolated immune complexes.

International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association·1993
Same author

Mode of action of antituberculous drugs and mechanisms of drug resistance in Mycobacterium tuberculosis.

Research in microbiology·1993

New Mycobacterium recombinant vaccines target difficult intracellular diseases by stimulating a protective TH-1 immune response. This approach uses novel antigen delivery and immuno-regulating adjuvants for lasting immunity against various pathogens.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Intracellular diseases pose significant challenges in modern medicine.
  • Immune responses, specifically T-helper 1 (TH-1) and T-helper 2 (TH-2) pathways, critically influence disease outcomes.
  • Current vaccines often lack specificity in immune response induction.

Purpose of the Study:

  • To develop a novel vaccine system for treating intracellular diseases.
  • To stimulate a protective TH-1 immune response crucial for combating intracellular pathogens.
  • To enhance vaccine efficacy through targeted immune pathway stimulation.

Main Methods:

  • Utilized a Mycobacterium recombinant vaccine system for antigen delivery.
  • Employed non-pathogenic Mycobacterium strains as delivery vehicles.

Related Experiment Videos

  • Incorporated cloning and expression vectors (pAL5000-based and D29-based) for genetic transfer.
  • Formulated vaccines with immuno-regulating Mycobacterium adjuvants, exogenous antigens, and TH-1 boosting cytokines.

    • Main Results:

    • The system delivers non-toxic, immuno-stimulating exogenous antigens specific to various diseases.
    • The vaccine formulation includes non-toxic immuno-regulating Mycobacterium adjuvants.
    • Cytokines were included in non-toxic amounts to specifically boost the TH-1 pathway.
    • The vaccine system is designed to provide lasting protective immunity.

    Conclusions:

    • The Mycobacterium recombinant vaccine system offers a promising strategy for treating intracellular diseases.
    • This approach effectively stimulates the desired TH-1 immune response, crucial for host protection.
    • The use of novel adjuvants and antigen delivery systems enhances vaccine efficacy and specificity.